Equillium, Inc. (EQ)
NASDAQ: EQ · Real-Time Price · USD
0.701
-0.017 (-2.35%)
Nov 21, 2024, 11:38 AM EST - Market open

Company Description

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.

The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis.

It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.

In addition, it serves dermatology, gastroenterology, rheumatology, hematology, transplant science, oncology, and pulmonology area.

Equillium, Inc. has a research collaboration agreement with Vivtex Corporation to develop GI-targeted formulations for Bi-specific peptide therapy.

The company was formerly known as Attenuate Biopharmaceuticals, Inc. and changed its name to Equillium, Inc. in May 2017.

Equillium, Inc. was incorporated in 2017 and is headquartered in La Jolla, California.

Equillium, Inc.
Equillium logo
Country United States
Founded 2017
IPO Date Oct 11, 2018
Industry Biotechnology
Sector Healthcare
Employees 44
CEO Bruce Steel

Contact Details

Address:
2223 Avenida De La Playa, Suite 105
La Jolla, California 92037
United States
Phone 858 240 1200
Website equilliumbio.com

Stock Details

Ticker Symbol EQ
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0001746466
CUSIP Number 29446K106
ISIN Number US29446K1060
Employer ID 82-1554746
SIC Code 2834

Key Executives

Name Position
Bruce D. Steel C.F.A. Co-Founder, President, Chief Executive Officer and Director
Daniel Mark Bradbury Executive Chairman
Christine Zedelmayer M.B.A., P.M.P. Senior Vice President and Chief Operating Officer
Dr. Stephen Connelly Ph.D. Chief Scientific Officer and Director
Jason A. Keyes Chief Financial Officer
Penny Tom Senior Vice President of Finance and Principal Accounting Officer
Michael Moore Vice President of Investor Relations and Corporate Communications
Dr. Matthew Ritter Ph.D. Senior Vice President of Corporate Development
Joel M. Rothman Chief Development Officer

Latest SEC Filings

Date Type Title
Nov 14, 2024 SC 13G/A [Amend] Statement of acquisition of beneficial ownership by individuals
Nov 14, 2024 144 Filing
Nov 13, 2024 10-Q Quarterly Report
Nov 13, 2024 8-K Current Report
Oct 31, 2024 144 Filing
Oct 31, 2024 8-K Current Report
Oct 31, 2024 8-K Current Report
Aug 8, 2024 10-Q Quarterly Report
Aug 8, 2024 8-K Current Report
Jul 23, 2024 8-K Current Report